Palvella Therapeutics, Inc (PVLA) Ownership
PVLA ownership summary
as of October 18, 2026- Institutions
- 103.8% of shares outstanding
- Insiders
- 11.21% of shares outstanding
- Shares outstanding
- 14.4M
- Float
- 10.7M shares available to trade
- Short interest
- 19.82% 2.5M shares short
- Days to cover
- 11.77 short interest up 8.5% vs prior month
- Institutions 103.84%
- Insiders 11.21%
PVLA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 7.88% | 1.1M | $136.6M | −18,090 (−1.6%) | June 30, 2026 |
| 2 | Jennison Associates LLC | 6.67% | 961K | $115.6M | +320,008 (+50.0%) | June 30, 2026 |
| 3 | BlackRock Inc | 6.37% | 918K | $110.5M | +231,504 (+33.7%) | June 30, 2026 |
| 4 | Frazier Life Sciences Management, L.P. | 6.12% | 882K | $106.2M | — | June 30, 2026 |
| 5 | First Light Asset Management, LLC | 5.36% | 772K | $92.9M | −208,857 (−21.3%) | June 30, 2026 |
| 6 | Bvf Inc | 4.67% | 673K | $80.9M | −288,200 (−30.0%) | June 30, 2026 |
| 7 | State Street Corp | 4.53% | 653K | $78.6M | +194,173 (+42.3%) | June 30, 2026 |
| 8 | T. Rowe Price Associates, Inc. | 4.43% | 639K | $76.9M | +236,304 (+58.7%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 3.57% | 514K | $61.8M | +36,500 (+7.6%) | June 30, 2026 |
| 10 | Frontier Capital Management CO Inc | 3.32% | 479K | $57.6M | +104,798 (+28.0%) | June 30, 2026 |
| 11 | Federated Hermes Inc | 3.01% | 433K | $52.1M | — | June 30, 2026 |
| 12 | Woodline Partners LP | 2.20% | 318K | $38.2M | — | June 30, 2026 |
| 13 | Orbimed Advisors LLC | 2.03% | 292K | $35.2M | +157,760 (+117.2%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 1.92% | 276K | $33.2M | +70,555 (+34.3%) | June 30, 2026 |
| 15 | Siren, L.L.C. | 1.79% | 257K | $31.0M | — | June 30, 2026 |
| 16 | PRIMECAP Management Company | 1.78% | 256K | $30.8M | +61,152 (+31.4%) | June 30, 2026 |
| 17 | AllianceBernstein L.P. | 1.76% | 253K | $30.5M | −9,667 (−3.7%) | June 30, 2026 |
| 18 | Eventide Asset Management, LLC | 1.61% | 231K | $27.8M | −1,764 (−0.8%) | June 30, 2026 |
| 19 | Emerald Advisers, LLC | 1.59% | 229K | $27.6M | +67,986 (+42.1%) | June 30, 2026 |
| 20 | FMR Inc | 1.49% | 215K | $25.8M | −967 (−0.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 1.5M shares and 6 cut 528K.
PVLA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.70% | 389K | $46.8M | −570 (−0.1%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.53% | 365K | $43.9M | −6,950 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.14% | 309K | $37.1M | −3,584 (−1.1%) | September 30, 2026 |
| 4 | Federated Hermes Kaufmann R | 1.92% | 277K | $33.3M | — | June 30, 2026 |
| 5 | PGIM Jennison Small Company A | 1.65% | 238K | $28.6M | — | August 31, 2026 |
| 6 | Eventide Healthcare & Life Sciences I | 1.61% | 231K | $27.8M | — | June 30, 2026 |
| 7 | PRIMECAP Odyssey Aggressive Growth | 1.45% | 209K | $25.1M | +45,350 (+27.7%) | June 30, 2026 |
| 8 | PGIM Jennison Health Sciences Z | 1.33% | 192K | $23.1M | — | August 31, 2026 |
| 9 | MEDICAL BioHealth EUR Acc | 1.23% | 177K | $21.3M | −17,465 (−9.0%) | August 31, 2026 |
| 10 | Federated Hermes Kaufmann Small Cap A | 1.04% | 150K | $18.1M | — | June 30, 2026 |
| 11 | T. Rowe Price New Horizons | 1.04% | 149K | $18.0M | −6,107 (−3.9%) | August 31, 2026 |
| 12 | Fidelity Small Cap Growth | 1.00% | 144K | $17.3M | +14,300 (+11.0%) | July 31, 2026 |
| 13 | Fidelity Small Cap Index | 0.83% | 120K | $14.4M | +1,088 (+0.9%) | July 31, 2026 |
| 14 | AB Small Cap Growth A | 0.77% | 111K | $13.4M | +7,898 (+7.6%) | August 31, 2026 |
| 15 | iShares Russell 2000 Growth ETF | 0.77% | 111K | $13.4M | −141 (−0.1%) | September 30, 2026 |
| 16 | T. Rowe Price Integrated US Sm Gr Eq | 0.73% | 106K | $12.7M | — | August 31, 2026 |
| 17 | Biotech Growth Ord | 0.71% | 103K | $12.4M | +10,412 (+11.3%) | June 30, 2026 |
| 18 | Principal SmallCap Growth I Instl | 0.67% | 96K | $11.5M | +3,273 (+3.5%) | August 31, 2026 |
| 19 | Fidelity Small Cap Growth K6 | 0.52% | 75K | $9.0M | +9,400 (+14.3%) | July 31, 2026 |
| 20 | William Blair Small Cap Growth I | 0.48% | 69K | $8.3M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
PVLA insider transactions
latest 6| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-18 | Kathleen Goin | Sell | $117.99 | 4,302 | $507,593 |
| 2026-02-27 | Elaine J Heron | Buy | $125.00 | 2,400 | $300,000 |
| 2026-02-27 | George M Jenkins | Buy | $125.00 | 4,000 | $500,000 |
| 2026-01-21 | Kathleen Goin | Sell | $97.63 | 4,302 | $420,004 |
| 2025-12-17 | Kathleen Goin | Sell | $96.47 | 4,302 | $415,014 |
| 2025-11-19 | Kathleen Goin | Sell | $86.23 | 4,302 | $370,961 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
PVLA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns PVLA
Institutional investors own 103.8% of Palvella Therapeutics's shares and insiders 11.21%. The largest holder is Suvretta Capital Management, LLC with 7.88% of the shares (1.1M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 6 reduced their stake in the latest filings. Short interest is 19.82% of the float, or 11.77 days of average trading volume. The share count rose 1,025.1% since 2016.
Related: PVLA analyst forecast, PVLA key metrics. See the PVLA stock overview for the latest quote and news.
PVLA ownership FAQ
Who owns the most Palvella Therapeutics stock?
The largest shareholders of Palvella Therapeutics are Suvretta Capital Management, LLC (7.88%), Jennison Associates LLC (6.67%), BlackRock Inc (6.37%), Frazier Life Sciences Management, L.P. (6.12%), First Light Asset Management, LLC (5.36%).
What percentage of Palvella Therapeutics is owned by institutions?
Institutions hold 103.8% of Palvella Therapeutics's shares outstanding; insiders hold 11.21%.
Which funds own Palvella Therapeutics?
The largest fund holders of Palvella Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.70%), State Street® SPDR® S&P® Biotech ETF (2.53%), iShares Russell 2000 ETF (2.14%), Federated Hermes Kaufmann R (1.92%), PGIM Jennison Small Company A (1.65%).
What is Palvella Therapeutics's short interest?
2.5M shares of Palvella Therapeutics were sold short, 19.82% of the float; at the average daily volume it would take 11.77 days to cover.
Are insiders buying or selling Palvella Therapeutics?
Of the latest 6 reported insider transactions in Palvella Therapeutics (since November 19, 2025), 2 were purchases and 4 were sales.
How many shares of Palvella Therapeutics are outstanding?
Palvella Therapeutics has 14.4M shares outstanding, of which 10.7M are in the public float.